Compare Biocon with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GSK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GSK PHARMA BIOCON /
GSK PHARMA
 
P/E (TTM) x 32.0 51.9 61.7% View Chart
P/BV x 3.8 11.7 32.6% View Chart
Dividend Yield % 0.3 1.4 19.1%  

Financials

 BIOCON    GSK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
GSK PHARMA
Mar-19
BIOCON /
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7073,595 19.7%   
Low Rs5541,253 44.2%   
Sales per share (Unadj.) Rs91.9184.7 49.8%  
Earnings per share (Unadj.) Rs16.726.3 63.6%  
Cash flow per share (Unadj.) Rs24.229.2 82.9%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.8 19.2%  
Book value per share (Unadj.) Rs101.6126.3 80.5%  
Shares outstanding (eoy) m600.00169.40 354.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.913.1 52.3%   
Avg P/E ratio x37.792.2 40.9%  
P/CF ratio (eoy) x26.183.1 31.4%  
Price / Book Value ratio x6.219.2 32.3%  
Dividend payout %6.076.1 7.9%   
Avg Mkt Cap Rs m378,330410,626 92.1%   
No. of employees `0006.15.0 123.6%   
Total wages/salary Rs m11,6535,372 216.9%   
Avg. sales/employee Rs Th8,994.36,306.7 142.6%   
Avg. wages/employee Rs Th1,900.71,083.1 175.5%   
Avg. net profit/employee Rs Th1,635.3898.0 182.1%   
INCOME DATA
Net Sales Rs m55,14431,281 176.3%  
Other income Rs m1,4441,023 141.1%   
Total revenues Rs m56,58832,304 175.2%   
Gross profit Rs m15,8836,009 264.3%  
Depreciation Rs m4,478486 921.4%   
Interest Rs m7096 11,816.7%   
Profit before tax Rs m12,1406,540 185.6%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m2,1232,373 89.5%   
Profit after tax Rs m10,0264,454 225.1%  
Gross profit margin %28.819.2 149.9%  
Effective tax rate %17.536.3 48.2%   
Net profit margin %18.214.2 127.7%  
BALANCE SHEET DATA
Current assets Rs m48,22820,061 240.4%   
Current liabilities Rs m30,37614,543 208.9%   
Net working cap to sales %32.417.6 183.5%  
Current ratio x1.61.4 115.1%  
Inventory Days Days6857 120.3%  
Debtors Days Days8614 608.1%  
Net fixed assets Rs m64,13014,343 447.1%   
Share capital Rs m3,0001,694 177.1%   
"Free" reserves Rs m57,98019,704 294.3%   
Net worth Rs m60,98021,398 285.0%   
Long term debt Rs m15,7662 788,300.0%   
Total assets Rs m121,92439,113 311.7%  
Interest coverage x18.11,091.0 1.7%   
Debt to equity ratio x0.30 276,619.7%  
Sales to assets ratio x0.50.8 56.6%   
Return on assets %8.811.4 77.2%  
Return on equity %16.420.8 79.0%  
Return on capital %16.831.9 52.5%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506534 2,903.7%   
Fx outflow Rs m10,3997,091 146.7%   
Net fx Rs m5,107-6,557 -77.9%   
CASH FLOW
From Operations Rs m11,5463,994 289.1%  
From Investments Rs m-7,138-1,433 498.0%  
From Financial Activity Rs m-2,417-3,584 67.4%  
Net Cashflow Rs m2,103-1,023 -205.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 50.7 40.6%  
Indian inst/Mut Fund % 8.4 10.2 82.4%  
FIIs % 10.7 23.8 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 102,036 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower, Dow Futures Down by 128 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 328 points, down 0.7% at 48,833 levels.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 12, 2021 01:52 PM

TRACK BIOCON

BIOCON - AJANTA PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS